Patents Assigned to Daiichi Sankyo Co., Ltd.
  • Publication number: 20170173112
    Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.
    Type: Application
    Filed: February 28, 2017
    Publication date: June 22, 2017
    Applicant: Daiichi Sankyo Co., Ltd.
    Inventors: Gabriele MATSCHINER, Christine ROTHE, Andreas HOHLBAUM, Andrea ALLERSDORFER, Rachida Siham Bel AIBA, Marlon HINNER, Alexander WIEDENMANN, Bradley LUNDE, Shinji YAMAGUCHI, Takahide ABURATANI, Ryuji HASHIMOTO, Tohru TAKAHASHI, Chikako NAGASAKI, Futoshi NARA, Tomohiro NISHIZAWA
  • Publication number: 20170166973
    Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low.
    Type: Application
    Filed: October 19, 2016
    Publication date: June 15, 2017
    Applicants: Daiichi Sankyo Co., Ltd., U3 Pharma GmbH, AMGEN, Inc.
    Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN
  • Publication number: 20170166654
    Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.
    Type: Application
    Filed: October 19, 2016
    Publication date: June 15, 2017
    Applicants: Daiichi Sankyo Co. Ltd., U3 Pharma GmbH, Kinki University, Amgen, Inc.
    Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN, Kimio YONESAKA, Kazuhiko NAKAGAWA
  • Publication number: 20170166615
    Abstract: The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules.
    Type: Application
    Filed: December 7, 2016
    Publication date: June 15, 2017
    Applicant: Daiichi Sankyo Co., Ltd.
    Inventors: GABRIELE MATSCHINER, Christine ROTHE, Alexander WIEDENMANN, Rachida Siham BEL AIBA, Marlon HINNER, Andrea ALLERSDORFER, Bradley LUNDE, Kazufumi KUBOTA, Mitsuhiro MAKINO, Sakiko TAKAHASHI, Ryuji HASHIMOTO, Tohru TAKAHASHI, Mamoru OTOYO
  • Patent number: 9598476
    Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: March 21, 2017
    Assignee: Daiichi Sankyo Co., Ltd.
    Inventors: Gabriele Matschiner, Christine Rothe, Andreas Hohlbaum, Andrea Allersdorfer, Rachida Siham Bel Aiba, Marlon Hinner, Alexander Wiedenmann, Bradley Lunde, Shinji Yamaguchi, Takahide Aburatani, Ryuji Hashimoto, Tohru Takahashi, Chikako Nagasaki, Futoshi Nara, Tomohiro Nishizawa
  • Publication number: 20160024161
    Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.
    Type: Application
    Filed: August 28, 2015
    Publication date: January 28, 2016
    Applicant: Daiichi Sankyo Co., Ltd.
    Inventors: Gabriele MATSCHINER, Christine Rothe, Andreas Hohlbaum, Andrea Allersdorfer, Rachida Siham Bel Aiba, Marlon Hinner, Alexander Wiedenmann, Bradley Lunde, Shinji Yamaguchi, Takahide Aburatani, Ryuji Hashimoto, Tohru Takahashi, Chikako Nagasaki, Futoshi Nara, Tomohiro Nishizawa
  • Patent number: 9150629
    Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: October 6, 2015
    Assignee: DAIICHI SANKYO CO., LTD.
    Inventors: Gabriele Matschiner, Christine Rothe, Andreas Hohlbaum, Andrea Allersdorfer, Rachida Siham Bel Aiba, Marlon Hinner, Alexander Wiedenmann, Bradley Lunde, Shinji Yamaguchi, Takahide Aburatani, Ryuji Hashimoto, Tohru Takahashi, Chikako Nagasaki, Futoshi Nara, Tomohiro Nishizawa
  • Patent number: 8969298
    Abstract: An effective liquid preparation achieves high bioavailability (BA) of physiologically active peptides or proteins, including ghrelins, that are administered as drugs. Also provided is a method for improving the BA of physiologically active peptides or proteins, including ghrelins, that are subcutaneously injected in aqueous solutions. The liquid preparation contains: a physiologically active peptide or protein, such as ghrelins, as an active ingredient; an acid solution including one or a combination of two or more selected form the group consisting of acetic acid, lactic acid, phosphoric acid, glycine, citric acid, hydrochloric acid, propionic acid, butyric acid, benzoic acid and salts thereof; an alcohol; and a polar organic liquid including one or a combination of two or more selected from the group consisting of N-methyl-2-pyrrolidone, dimethylformamide, dimethylsulfoxide and methylparaben.
    Type: Grant
    Filed: August 2, 2010
    Date of Patent: March 3, 2015
    Assignees: Daiichi Sankyo Co., Ltd.
    Inventors: Masaru Matsumoto, Masako Matsumoto, Takeshi Hanada, Naomi Wakabayashi
  • Publication number: 20130280282
    Abstract: Ligand Drug Conjugates are provided having a DR5 binding moiety attached via linking groups and/or spacers to a therapeutic agent that are effective in treatment of various cancers.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 24, 2013
    Applicants: Daiichi Sankyo Co., Ltd., Seattle Genetics, Inc.
    Inventors: Toshiaki Ohtsuka, Kimihisa Ichikawa, Ayumi Yada
  • Publication number: 20130197072
    Abstract: Methods for manufacturing neuraminic acid compounds and synthetic intermediates of neuraminic acid compounds, including a method for manufacturing a compound represented by wherein R2 represents a C1-C4 alkyl, R3 represents a C1-C6 alkyl, R4 and R5 represent a hydrogen atom, a C1-C6 alkyl or a phenyl, or R4 and R5 together form a tetramethylene, a pentamethylene or an oxo, and Ac represents an acetyl, comprising reacting a compound represented by wherein R2 represents a C1-C4 alkyl, R3 represents a C1-C6 alkyl, R4 and R5 represent a hydrogen atom, a C1-C6 alkyl or a phenyl, or R4 and R5 together form a tetramethylene, a pentamethylene or an oxo, with trimethylsilyl azide in the presence of a Lewis acid.
    Type: Application
    Filed: March 12, 2013
    Publication date: August 1, 2013
    Applicant: DAIICHI SANKYO CO., LTD.
    Inventor: DAIICHI SANKYO CO., LTD.
  • Patent number: 8168392
    Abstract: By finding a novel tetrahydrofolate synthetase gene and a protein encoded by said gene, a method for identifying a compound which inhibits cell growth accelerating activity of said protein is provided, and a judging method, a preventing method and a treating method of colon cancer are provided. A DNA comprising a nucleotide sequence of from the 94th to 2934th positions of the nucleotide sequence of SEQ ID NO:1 of the SEQUENCE LISTING; a polynucleotide which specifically hybridizes with said DNA; a protein encoded by said DNA; a recombinant vector comprising said DNA; a transformant comprising said recombinant vector; an antibody for said protein; a method for producing said protein; a method for identifying a compound which inhibits cell growth accelerating activity possessed by said protein; a method for judging colon cancer, characterizing in that expressed amount of said DNA is measured; a kit for judging colon cancer; a preventive agent and/or therapeutic agent for colon cancer.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: May 1, 2012
    Assignee: Daiichi Sankyo Co., Ltd.
    Inventor: Takeyuki Sugiura
  • Publication number: 20110070248
    Abstract: Ligand Drug Conjugates are provided having a DR5 binding moiety attached via linking groups and/or spacers to a therapeutic agent and are effective in treatment of various cancers.
    Type: Application
    Filed: September 23, 2010
    Publication date: March 24, 2011
    Applicants: Seattle Genetics, Inc., Daiichi Sankyo Co., Ltd.
    Inventors: Kimihisa Ichikawa, Kosaku Fujiwara, Hiroko Yoshida, Ayumi Yada
  • Patent number: 7468268
    Abstract: A protein which inhibits osteoclast differentiation and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.
    Type: Grant
    Filed: August 31, 2004
    Date of Patent: December 23, 2008
    Assignee: Daiichi Sankyo Co., Ltd.
    Inventors: Masaaki Goto, Eisuke Tsuda, Shin'ichi Mochizuki, Kazuki Yano, Fumie Kobayashi, Nobuyuki Shima, Hisataka Yasuda, Nobuaki Nakagawa, Tomonori Morinaga, Masatsugu Ueda, Kanji Higashio
  • Patent number: 7306791
    Abstract: The present invention provides methods of preventing and/or treating multiple organ failure comprising the step of administering a therapeutically effective amount of agent comprising tumor cytotoxic factor-II (TCF-II) or hepatocyte growth factor (HGF). Methods of the present invention will be useful for preventing and/or treating the development of multiple organ failure resulting from burn, disseminated intravascular coagulation (DIC), circulatory failure, hemorrhagic shock, infectious disease, acute pancreatitis, ischemic disorder, hepatorenal syndrome, gastrointestinal hemorrhage, nutritional metabolic failure, terminal cancer, acquired immunodeficiency syndrome (AIDS), deterioration of systemic conditions due to radiation affection, and cachexia.
    Type: Grant
    Filed: December 11, 2002
    Date of Patent: December 11, 2007
    Assignee: Daiichi Sankyo Co., Ltd.
    Inventors: Hirohiko Arisawa, Hiroaki Masunaga, Hiromi Ogawa, Kanji Higashio